EOLS News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

EO

Mkt Cap

$468.6M

Volume

620.01K

Next Earnings

November 4th

Loading chart

EO

EOLSEvolus, Inc. Common Stock

EOLS

Pay with—

Available Balance0.00

EO

Mkt Cap

$469.0M

Volume

620.01K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

UTMD Trades at a Premium to the Industry: How to Play the Stock?Utah Medical Products (UTMD) trades at a premium valuation of 4.05X EV/sales versus industry average of 2.68X. While the company benefits from strong margins (58.2% gross margin), a debt-free balance sheet with $87.5M in cash, and strategic acquisitions, it faces near-term headwinds including 12.3% revenue decline, major customer losses, and projected 10-13% revenue decline for 2026. Long-term investors may hold, but new investors should await a better entry point.Zacks Investment Research · Oct 8, 2026

AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache SocietyAEON Biopharma announced presentation of analytical and functional data supporting biosimilarity of ABP-450 to BOTOX® at the American Headache Society meeting. The data demonstrates highly similar biological activity through multiple analytical approaches, with LC-MS peptide mapping showing 93%-99% sequence coverage and LD50 potency assay results falling within equivalence criteria established from BOTOX® reference results.GlobeNewswire Inc. · Jun 4, 2026

Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing ItConexeu Sciences Inc. (CNXU) commenced trading on Nasdaq on May 21, 2026, as a regenerative tissue platform company. The company's proprietary CXU™ extracellular matrix platform is designed to scale across multiple markets including wound care, breast reconstruction, and aesthetic medicine without reformulation. The company targets a 510(k) submission in early 2027 and holds issued patents across major markets with no royalty obligations.Benzinga · May 22, 2026

ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked AwayStonepine Capital Management fully exited its position in ANI Pharmaceuticals, selling 38,597 shares worth $2.52 million in Q3. Despite ANI's strong fundamentals—with Q3 revenue surging 54% YoY to $227.8 million and stock up 49% over the past year—the fund's exit appears to be a portfolio rebalancing move toward earlier-stage biotech rather than a loss of confidence. ANI's future returns will depend on sustained rare disease growth and margin discipline rather than multiple expansion.The Motley Fool · Dec 28, 2025

AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711AEON Biopharma announced the grant of 392,158 restricted stock units to newly hired non-executive employees on December 11, 2025, under its 2025 Inducement Incentive Plan. The RSUs vest over four years with 25% vesting annually. The company continues development of ABP-450, a BOTOX biosimilar targeting the $3 billion U.S. therapeutic neurotoxin market.GlobeNewswire Inc. · Dec 19, 2025

Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med SpasThe article discusses the debut of Chinese boba tea chain Mixue on the Hong Kong stock exchange, the departure of Kroger's CEO due to personal conduct issues, and Domino's introduction of stuffed crust pizza. It also covers the booming med spa industry and the performance of Evolus, a competitor to Botox.The Motley Fool · Mar 10, 2025

Rare Stock Picks In May 2024 - From 29 Discerning AnalystsIn our monthly Rare Stock Picks series, we're highlighting May 2024 investment picks. Click here for the list of May 2024 Buy recommendations.Seeking Alpha · Jun 6, 2024

Evolus (EOLS) Releases Favorable Dermal Fillers Study DataThe addition of Evolysse fillers to the company's portfolio complements Evolus' (EOLS) flagship neurotoxin Jeuveau.Zacks Investment Research · May 21, 2024

Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue EstimatesEvolus (EOLS) delivered earnings and revenue surprises of -85.71% and 0.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 7, 2024

4 Stocks to Keep a Tab on for Amazing Earnings AccelerationNotable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).Zacks Investment Research · May 3, 2024

to start trading

EO

EOLSEvolus, Inc. Common Stock

EOLS

Pay with—

Available Balance0.00

Your PositionYou don't own any EOLS yet.

Related Tickers

Earnings